Skip to Content
Merck
CN

EHU123751

MISSION® esiRNA

targeting human CLDN5

Sign In to View Organizational & Contract Pricing

Select a Size

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CAGGCTCCTCGGAACGTCCGGCTCTGCGCCCCGACGCGGCTCCTGGATCCGCTCCTGCCTGCGCCCGCAGCTGACCTTCTCCTGCCACTAGCCCGGCCCTGCCCTTAACAGACGGAATGAAGTTTCCTTTTCTGTGCGCGGCGCTGTTTCCATAGGCAGAGCGGGTGTCAGACTGAGGATTTCGCTTCCCCTCCAAGACGCTGGGGGTCTTGGCTGCTGCCTTACTTCCCAGAGGCTCCTGCTGACTTCGGAGGGGCGGATGCAGAGCCCAGGGCCCCCACCGGAAGATGTGTACAGCTGGTCTTTACTCCATCGGCAGGGCCCGAGCCCAGGGACCAGTGACTTGGCCTGGACCTCCCGGTCTCACTCCAGCATCTCCCCAGGCAAGGCTTGTGGGCACCGGAGCTTGAGAGAGGGCGGGAGTGGGAAGGCTAAGAATC

Ensembl | human accession no.

ENSG00000184113

NCBI accession no.

NM_001130861

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... CLDN5(7122), CLDN5(7122)

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
EXR
DOR

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yanan Jia et al.
American journal of translational research, 11(9), 5546-5559 (2019-10-22)
The combination of anti-angiogenesis and chemotherapy can significantly prolong the survival period of patients with non-squamous non-small cell lung cancer (NSCLC). But drug resistance will inevitably occur, thereby causing increased tumor invasion and metastasis. Claudin-5 (CLDN5) is a protein member
Christine M Gross et al.
American journal of respiratory cell and molecular biology, 58(5), 614-624 (2017-11-09)
One of the early events in the progression of LPS-mediated acute lung injury in mice is the disruption of the pulmonary endothelial barrier resulting in lung edema. However, the molecular mechanisms by which the endothelial barrier becomes compromised remain unresolved.
Natalie Hudson et al.
JCI insight, 4(15) (2019-08-09)
Age-related macular degeneration (AMD) is the leading cause of central retinal vision loss worldwide, with an estimated 1 in 10 people over the age of 55 showing early signs of the condition. There are currently no forms of therapy available

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service